REGISTER
Why Lung Cancer Drugs Need Earlier Multinational Trials | Alex A. Adjei at WCLC 2026
At WCLC 2026, Prof. Alex A. Adjei discusses how targeted therapies and immunotherapy have transformed thoracic oncology and contributed to JTO’s academic growth. He highlights China’s expanding role in developing ADCs and other cancer treatments, while calling for earlier multinational trials and stronger cross-border collaboration so promising innovations can reach patients worldwide more quickly and equitably.

At WCLC 2026, Prof. Alex A. Adjei reflects on JTO’s growing influence, the transformation of thoracic oncology, and the need to make emerging treatments globally accessible.

Organized by the International Association for the Study of Lung Cancer, WCLC 2026 took place in Seoul, Republic of Korea, from September 12 to 15.

Prof. Alex A. Adjei is Director of the Taussig Cancer Institute at Cleveland Clinic, Editor-in-Chief of the Journal of Thoracic Oncology, and Founding Editor-in-Chief of JTO Clinical and Research Reports.

Key highlights from this clip:

● How targeted therapies and immunotherapy transformed lung cancer research

● Why scientific progress and editorial quality contributed to JTO’s growth

● China’s expanding role in developing ADCs, targeted therapies, and immunotherapies

● The access gap when promising treatments are initially available in only one country

● Why new drugs should enter multinational studies earlier in development

● How cross-border collaboration could bring innovation to patients more quickly worldwideThis video is intended for medical education and professional discussion.

0
0
Loading